Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TrazoFlex
- Development stage
- Unknown
- Lead developer
- Spektus Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TrazoFlex is a reformulated version of the antidepressant trazodone, developed by Spektus Pharma using proprietary drug delivery platforms such as Flexitab™ and AmyloFlex™. It is an oral solid formulation designed for the treatment of depression, utilizing the 505(b)(2) regulatory pathway for improved delivery profiles. As a Serotonin Antagonist and Reuptake Inhibitor (SARI), the active ingredient trazodone exerts its therapeutic effects by inhibiting the serotonin transporter (SERT) and antagonizing the 5-HT2A receptor. The product line includes TrazoFlex 24 (extended-release) and TrazoFlex CR (controlled-release), both aimed at optimizing the pharmacokinetic profile of trazodone for better patient outcomes in major depressive disorder.
- Brand names
- TrazoFlexTrazoFlex 24TrazoFlex24TrazoFlex-24TrazoFlex CR
- Other names
- trazodone (reformulation)trazodone extended-releasetrazodone controlled-release
02
Targets
ADRA1A (α1A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR7 (5-hydroxytryptamine receptor 7)DNASERT (Sodium-dependent serotonin transporter)H (Histamine receptors)
Beyond the preview
Go deeper on TrazoFlex.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TrazoFlex.